Related Experiment Video

Updated: Sep 20, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Celiprolol and atenolol in angina--effects on left ventricular function

H Dargie1, J M McLenachan, J T Wilson

  • 1Department of Cardiology, Western Infirmary, Glasgow, UK.

The Journal of International Medical Research
|January 1, 1988
PubMed

Insights

Celiprolol and atenolol both improved stable angina symptoms. Celiprolol demonstrated a unique benefit by prolonging exercise time and potentially offering advantages due to its ancillary properties.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Stable angina pectoris is a common cardiovascular condition.
  • Beta-blockers are a cornerstone therapy for angina management.

Purpose of the Study:

  • To compare the efficacy and cardiac effects of celiprolol and atenolol in patients with stable angina.
  • To investigate the influence of celiprolol's unique pharmacological properties on cardiac function during exercise.

Main Methods:

  • A double-blind, placebo-controlled, crossover study involving 16 patients with stable angina.
  • Patients received celiprolol (400 mg once daily) and atenolol (100 mg once daily).
  • Evaluated angina frequency, exercise tolerance, heart rate, and cardiac output.

Main Results:

  • Both celiprolol and atenolol reduced angina frequency and delayed exercise-induced ischemia.
  • Only celiprolol significantly prolonged exercise duration.
  • Celiprolol caused less heart rate suppression during exercise compared to atenolol.
  • Atenolol, but not celiprolol, reduced resting and exercise cardiac output.

Conclusions:

  • Celiprolol and atenolol are effective in managing stable angina symptoms.
  • Celiprolol's partial beta-2 adrenoceptor agonist and vasodilating activities may confer additional benefits in angina patients.
  • These ancillary properties of celiprolol may lead to improved cardiac function and exercise capacity.

More Related Videos

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...